Rasagilin Krka 1 mg

Rasagilin Krka is a generic medication containing the active substance rasagiline, primarily used for the treatment of Parkinson's disease. It is a monoamine oxidase B (MAO-B) inhibitor that helps increase dopamine levels in the brain to manage symptoms such as tremors and rigidity. The product is manufactured by Krka, d. d., which is headquartered in Slovenia, with additional production facilities in Germany (through its subsidiary TAD Pharma) and other regions.

The brand originated in Slovenia, where the parent company Krka was founded in 1954 as a state-owned pharmaceutical laboratory. Over the decades, Krka evolved into a major international public limited company. While it is listed on the Ljubljana Stock Exchange and has a diverse range of international shareholders, the Slovenian state remains the most significant ultimate owner through various holding companies, ensuring the brand maintains its national identity while operating globally.